By Karen Blum
National Harbor, Md.—While immunotherapy has been extremely successful for some patients, it’s still early with regard to understanding cancer immunology and predicting which patients will benefit and what time course of treatment is best, according to a panel of experts at the 2016 annual meeting of the Society for Immunotherapy of Cancer.
When Genentech was conducting clinical trials of atezolizumab (Tecentriq) that provided treatment for a year, the investigators